Assay News and Research

RSS

JCO publishes Syndax erlotinib-entinostat Phase 2 study for advanced non-small cell lung cancer

Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).

30 Apr 2012

New test accurately detects aggressive prostate cancer

One in six men will be diagnosed with prostate cancer during his lifetime, the second leading cause of death among men in the United States. It's a serious problem and current diagnostic tests aren't very specific. But a research team at the University of Central Florida NanoScience Technology Center has found a more accurate test that not only determines whether a patient has prostate cancer, but also how aggressive it is.

26 Apr 2012

Leica receives FDA Pre-Market Approval for new HER2 IHC test

Leica Biosystems, a division of Leica Microsystems, announced that it has received Pre-Market Approval from the U.S. Food and Drug Administration for the Leica Bond Oracle HER2 IHC System with the Leica BOND-MAX, establishing their commitment to developing quality companion diagnostic products.

26 Apr 2012

Immunosignatures can yield reliable and highly stable diagnostic results

Identifying diseases at an early, presymptomatic stage may offer the best chance for establishing proper treatment and improving patient outcomes. A new technique known as immunosignaturing harnesses the human immune system as an early warning sentry-one acutely sensitive to changes in the body that may be harbingers of illness.

24 Apr 2012

Oligomerix to advance tau protease inhibitor program with $2M Series A financing

Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease and related neurodegenerative disorders, announced today the completion of approximately $2 million in Series A financing, which includes both issuance of new convertible preferred shares and debt conversion.

23 Apr 2012

Developments in mesothelioma treatment presented at 3rd European Lung Cancer Conference

New results presented at 3rd European Lung Cancer Conference in Geneva, Switzerland show important steps being made to improve the diagnosis and treatment of malignant pleural mesothelioma, an aggressive cancer of the outer lining of the lungs caused by asbestos exposure.

19 Apr 2012

Differentiated luminal-like breast cancer cells can generate larger tumors

New findings in breast cancer research by an international team of scientists contradict the prevailing belief that only basal-like cells with stem cell qualities can form invasive tumors. Research led by Ole William Petersen at the University of Copenhagen (CU) and Mina Bissell of the Lawrence Berkeley National Laboratory (Berkeley Lab) and has shown that luminal-like cells with no detectable stem cell qualities can generate larger tumors than their basal-like counterparts.

19 Apr 2012

No added HIV risk with hormonal contraceptives

An HIV prevention trial that pre-dates the shift to antiretroviral (ARV)-based approaches is nonetheless helping to answer some of the most relevant and topical questions the field is facing today.

18 Apr 2012

Study finds lower cytokine levels in the plasma of children with autism

A University of Kansas Medical Center study found significantly lower levels of several cytokines, the immune system's messengers and regulators, in the plasma of children with autism disorder (AD) compared to that of unrelated healthy siblings from other families who had members with autism spectrum disorders.

17 Apr 2012

FDA grants 510(k) clearance for QIAGEN’s molecular detection PCR technology

QIAGEN N.V. today announced that the U.S. Food and Drug Administration (FDA) has granted two 510(k) clearances for its real-time PCR (polymerase chain reaction) instrument Rotor-Gene Q MDx and a compatible test for the detection of Influenza A/B, the artus Infl A/B RG RT-PCR Kit, for in vitro diagnostic use.

From QIAGEN Manchester Limited 17 Apr 2012

RiboMed releases multi-marker methylation prognostic test for glioma

RiboMed Clinical Services Laboratory (RCSL), a CLIA-certified subsidiary of RiboMed Biotechnologies, today announced the release of a multi-marker methylation prognostic test for grading gliomas, the most common type of brain cancer.

12 Apr 2012

FDA approves Medtronic’s expanded indication for implantable CRT-D devices

Medtronic, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for its cardiac resynchronization therapy with implantable cardioverter defibrillator (CRT-D) devices.

From Medtronic 11 Apr 2012

New WHO endorsed diagnostic tool for TB

Up to 30% of the world's population is infected with Tuberculosis (TB), but in many areas of the world, TB diagnosis still relies on insensitive, poorly standardized, and time-consuming methods. A new diagnostic tool, endorsed by the World Health Organization (WHO), may change that. Dr. Thomas Bodmer shows how it's done in the Journal of Visualized Experiments (JoVE).

9 Apr 2012

Applied BioCode receives U.S. patent titled, ‘Light Transmitted Assay Beads’

Applied BioCode, Inc. today announced that the United States Patent and Trademark Office has issued US Patent #8,148,139 "Light Transmitted Assay Beads," describing the method of use and manufacturing of its Barcoded Magnetic Beads (BMB) products.

5 Apr 2012

Scripps Florida scientists to create new screening tests for HCV treatment discovery

Scientists from the Florida campus of The Scripps Research Institute have been awarded just over $1 million from the National Institutes of Health for a three-year study to develop new high-throughput screening tests to find compounds that disable a protein essential to hepatitis C virus (HCV) replication.

5 Apr 2012

BioScale presents data on phospho-protein analysis of MAP kinase pathway activation state at 103rd AACR

BioScale, Inc. a life science company that develops ultrasensitive protein analysis technology, presented findings of recently completed research studies on phospho-protein analysis of the activation state of the MAP kinase pathway at the 103rd Annual Meeting of the American Association for Cancer Research (AACR), held at McCormick Place in Chicago, Illinois, March 31 - April 4, 2012.

3 Apr 2012

InstantLabs receives PTM certification for Salmonella Species Food Safety Kit

InstantLabs Medical Diagnostics Corporation, developer of the portable Hunter Accelerated Real-Time PCR system, today announced that its Salmonella Species Food Safety Kit has been certified as Performance-Tested Methods (PTM) No. 031202 by the AOAC Research Institute.

3 Apr 2012